Stocktoria
Inmune Bio, Inc. INMB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-04
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M | -$29.2M |
| Net income | -$45.9M | -$42.1M | -$30.0M | -$27.3M | -$30.3M |
| Operating cash flow | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M |
| Free cash flow | -$23.6M | — | — | — | — |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M |
| Shareholders' equity | $23.5M | $32.1M | $37.3M | $60.1M | $80.2M |
| Ratios | |||||
| Operating margin | -94766.0% | -304535.7% | -19187.7% | -6938.8% | -16106.6% |
| Net margin | -91866.0% | -300585.7% | -19360.0% | -7299.2% | -16762.4% |
| FCF margin | -47248.0% | — | — | — | — |
| Return on assets | -142.0% | -106.4% | -52.6% | -33.4% | -30.4% |
| Return on equity | -195.3% | -131.1% | -80.4% | -45.4% | -37.8% |
| Debt / equity | — | 0.47× | — | 0.16× | 0.19× |
| Current ratio | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 |
| Revenue growth | 257.1% | -91.0% | -58.6% | 106.6% | 1545.5% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 17,000 | $19,210 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001711754 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.